• Je něco špatně v tomto záznamu ?

Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application

J. Hynst, V. Navrkalova, K. Pal, S. Pospisilova

. 2021 ; 9 (-) : e10897. [pub] 20210331

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018055

Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection. This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels. Such panels enable a relatively inexpensive and rapid analysis of various aberrations with clinical impact specific to particular diagnoses. In this review, we discuss the experimental approaches and bioinformatic strategies available for the development of an NGS panel for a reliable analysis of selected biomarkers. Compliance with defined analytical steps is crucial to ensure accurate and reproducible results. In addition, a careful validation procedure has to be performed before the application of NGS targeted assays in routine clinical practice. With more focus on bioinformatics, we emphasize the need for thorough pipeline validation and management in relation to the particular experimental setting as an integral part of the NGS method establishment. A robust and reproducible bioinformatic analysis running on powerful machines is essential for proper detection of genomic variants in clinical settings since distinguishing between experimental noise and real biological variants is fundamental. This review summarizes state-of-the-art bioinformatic solutions for careful detection of the SNV/Indels and CNVs for targeted sequencing resulting in translation of sequencing data into clinically relevant information. Finally, we share our experience with the development of a custom targeted NGS panel for an integrated analysis of biomarkers in lymphoproliferative disorders.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018055
003      
CZ-PrNML
005      
20210729104210.0
007      
ta
008      
210726s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.7717/peerj.10897 $2 doi
035    __
$a (PubMed)33850640
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hynst, Jakub $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic
245    10
$a Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application / $c J. Hynst, V. Navrkalova, K. Pal, S. Pospisilova
520    9_
$a Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection. This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels. Such panels enable a relatively inexpensive and rapid analysis of various aberrations with clinical impact specific to particular diagnoses. In this review, we discuss the experimental approaches and bioinformatic strategies available for the development of an NGS panel for a reliable analysis of selected biomarkers. Compliance with defined analytical steps is crucial to ensure accurate and reproducible results. In addition, a careful validation procedure has to be performed before the application of NGS targeted assays in routine clinical practice. With more focus on bioinformatics, we emphasize the need for thorough pipeline validation and management in relation to the particular experimental setting as an integral part of the NGS method establishment. A robust and reproducible bioinformatic analysis running on powerful machines is essential for proper detection of genomic variants in clinical settings since distinguishing between experimental noise and real biological variants is fundamental. This review summarizes state-of-the-art bioinformatic solutions for careful detection of the SNV/Indels and CNVs for targeted sequencing resulting in translation of sequencing data into clinically relevant information. Finally, we share our experience with the development of a custom targeted NGS panel for an integrated analysis of biomarkers in lymphoproliferative disorders.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Navrkalova, Veronika $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Pal, Karol $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Pospisilova, Sarka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic
773    0_
$w MED00184567 $t PeerJ $x 2167-8359 $g Roč. 9, č. - (2021), s. e10897
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33850640 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104209 $b ABA008
999    __
$a ind $b bmc $g 1676519 $s 1138497
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c - $d e10897 $e 20210331 $i 2167-8359 $m PeerJ $n PeerJ $x MED00184567
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace